8-K: Tvardi Reports Q3 2025: IPF Trial Fails, Liver Cancer Data Awaited

Tvardi Therapeutics announced mixed third-quarter 2025 results, with a key IPF trial failing to meet its goals, but progress in oncology programs and an extended cash runway into Q4 2026.

Summary

• Tvardi Therapeutics reported financial and operating results for the third quarter ended September 30, 2025.
• The Phase 2 REVERT IPF trial for TTI-101 did not meet its goals, with additional analyses underway to determine next steps.
• The company continues to progress its Phase 2 study of TTI-101 in hepatocellular carcinoma (HCC), with topline data anticipated in the first half of 2026.
• An Investigational New Drug (IND) for TTI-109, a next-generation STAT3 inhibitor, is in effect, and a healthy volunteer study has been initiated, with results expected in the first half of 2026.
• Cash, cash equivalents, and short-term investments totaled $36.5 million as of September 30, 2025, up from $31.6 million at December 31, 2024.
• The current cash runway is projected to fund operations into the fourth quarter of 2026.
• Net loss for Q3 2025 was $5.5 million, roughly flat compared to $5.5 million in Q3 2024.
• Basic and diluted net loss per share improved to $(0.59) in Q3 2025 from $(2.14) in Q3 2024, primarily due to an increased weighted-average common share count.

Sentiment

Score: 5

Explanation: The sentiment is mixed. The failure of the IPF trial is a significant negative, impacting a key program. However, progress in the HCC program, the advancement of a next-generation candidate (TTI-109), and an extended cash runway provide some positive counterbalance. The financial position improved significantly in terms of equity, likely due to a capital raise, but the company continues to incur net losses.

Positives

• Cash, cash equivalents, and short-term investments increased to $36.5 million as of September 30, 2025, from $31.6 million at December 31, 2024.
• The company has extended its cash runway, anticipating sufficient funds to support operations into the fourth quarter of 2026.
• Progress continues in the Phase 2 REVERT Liver Cancer trial for TTI-101, with interim results showing clinically meaningful activity in oncology.
• The next-generation STAT3 inhibitor, TTI-109, has initiated a healthy volunteer study following IND approval, strengthening the company's pipeline.
• Net loss per share significantly improved to $(0.59) for Q3 2025, compared to $(2.14) for Q3 2024, despite a flat net loss, indicating a more favorable per-share financial position.

Negatives

• The Phase 2 REVERT IPF trial for TTI-101 did not meet its goals, leading to further analysis to determine the path forward for this program.
• General and administrative expenses increased by approximately $1.5 million to $2.3 million for Q3 2025, primarily due to higher professional fees, personnel costs, insurance, and rent.
• The accumulated deficit increased to $(103.175) million as of September 30, 2025, from $(92.236) million as of December 31, 2024.

Risks

• Uncertainties associated with product candidates, clinical development, and regulatory approval, including potential delays in trial completion.
• The company has incurred significant net losses since inception.
• Ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance product candidates through clinical development.
• The timing of the availability of data from clinical trials.
• The outcome of preclinical testing and clinical trials, including the ability to satisfy relevant governmental or regulatory requirements.
• The requirement for additional capital to continue advancing product candidates, which may not be available on favorable terms or at all.
• Ability to attract, hire, and retain skilled executive officers and employees.
• Ability to protect intellectual property and proprietary technologies.
• Reliance on third parties, contract manufacturers, and contract research organizations.
• The possibility of being adversely affected by other economic, business, or competitive factors.
• Risks associated with changes in applicable laws or regulations.

Future Outlook

The company anticipates preliminary topline data from its ongoing REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 in the first half of 2026. Additionally, preliminary topline data from a healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, is also expected in the first half of 2026. Tvardi projects its current cash runway to be sufficient to fund operations into the fourth quarter of 2026.

Management Comments

• While we continue to analyze the results from our REVERT IPF clinical trial to determine the most appropriate path forward, we remain confident in the potential of STAT3 inhibition to address fibrosis-driven diseases.
• Our lead program, TTI-101, has demonstrated encouraging clinical activity in oncology and continues to hold promise across a range of indications where STAT3 is a key driver.
• We eagerly await data from our ongoing Phase 2 REVERT Liver Cancer trial in the first half of next year, where interim results have already shown clinically meaningful activity of TTI-101 both as monotherapy and in combination with established anti-cancer agents across treatment lines.
• We are also advancing our next-generation STAT3 inhibitor, TTI-109, through a healthy volunteer study, which is designed to rapidly convert to TTI-101 and lessen the exposure of the active drug to the intestinal lining, potentially improving tolerability.
• With a balance sheet extending into the fourth quarter of next year, we remain focused on fully realizing the therapeutic potential of STAT3 inhibition across fibrotic diseases.

Industry Context

Tvardi Therapeutics operates in the highly competitive biopharmaceutical industry, specifically targeting fibrosis-driven diseases and oncology through STAT3 inhibition. STAT3 is a recognized central mediator in various fibrotic signaling pathways and cancer cell survival. The development of novel, oral small molecule therapies in this space faces intense competition from other pharmaceutical companies developing similar or alternative treatments for conditions like hepatocellular carcinoma and idiopathic pulmonary fibrosis. The success of Tvardi's pipeline, particularly TTI-101 and TTI-109, will depend on demonstrating superior efficacy and safety profiles compared to existing and emerging therapies.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks, comparable companies, or projects regarding clinical trial results or financial performance.

Stakeholder Impact

• Shareholders: Face a setback with the IPF trial failure, but benefit from an extended cash runway and progress in other pipeline assets. The significant increase in common shares outstanding indicates dilution from a recent capital raise.
• Patients: Those with IPF may be disappointed by the trial results, while patients with HCC and other fibrosis-driven diseases may see continued hope from ongoing clinical programs.
• Employees: The company's continued operations and pipeline advancement suggest stability, but the IPF trial setback could impact morale or strategic focus.

Next Steps

• Conduct additional analyses to further understand the results of the REVERT IPF trial and inform next steps for the program.
• Anticipate preliminary topline data from the REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 in the first half of 2026.
• Anticipate preliminary topline data from the healthy volunteer study of TTI-109 in the first half of 2026.

Key Dates

Recommendation

The stock warrants a 'hold' recommendation due to mixed signals. The failure of the Phase 2 IPF trial is a significant negative development for one of the company's key programs, which could weigh on investor sentiment. However, the company has demonstrated progress in its TTI-101 HCC program with encouraging interim data and is advancing a next-generation STAT3 inhibitor, TTI-109. Crucially, the company has secured its financial position with a cash runway extending into Q4 2026, likely through a recent capital raise that significantly improved its balance sheet. Investors should await the upcoming topline data from the REVERT Liver Cancer trial and TTI-109 healthy volunteer study in H1 2026 to gain clearer insights into the company's future prospects before making a definitive 'buy' or 'sell' decision.

Keywords

Biopharmaceutical, STAT3 inhibitor, TTI-101, TTI-109, Hepatocellular Carcinoma, HCC, Idiopathic Pulmonary Fibrosis, IPF, Clinical Trials, Oncology, Fibrosis, Drug Development, Q3 2025 Results